Actavis gets green light for generic Keppra XR, launches product

MORRISTOWN, N.J. — Actavis has launched its version of an epilepsy drug made by UCB.

The generic drug maker said it received approval from the Food and Drug Administration for levetiracetam extended-release tablets and commenced shipping the product following approval. The drug is the generic equivalent of Keppra XR.

U.S. sales of Keppra XR were about $161 million for the 12 months ended June 30, according IMS Health data.